Trial Profile
Safety and effectiveness of novel direct antiviral agents (sofosbuvir, ribavirin, simeprevir, daclatasvir, ledipasvir, paritaprevir/r and ombitasvir ± dasabuvir) in patients with chronic hepatitic C and advanced chronic kidney disease: A German Hepatitis C-Registry (DHC-R) study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir (Primary) ; Ledipasvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018